Description
Manufacturer:
Sun Pharmaceutical Industries Ltd
Salt Composition:
Fenofibrate
Description:
Stanlip-145mg Tablet contains fenofibrate, a fibric acid derivative primarily indicated for the treatment of hypertriglyceridemia (high triglyceride levels) and mixed dyslipidemia (elevated triglycerides and low high-density lipoprotein cholesterol).
Fenofibrate works by activating peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor that regulates lipid metabolism. Activation of PPARα leads to increased lipolysis (breakdown of fats) and elimination of triglyceride-rich lipoproteins from the plasma. It also increases the synthesis of apolipoprotein A-I, a major component of HDL cholesterol, thus raising HDL levels.
Stanlip-145mg is often used in conjunction with dietary modifications and lifestyle changes to manage abnormal lipid levels and reduce the risk of cardiovascular events associated with dyslipidemia. It is typically administered once daily, usually with food to enhance absorption. Common side effects may include gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, as well as elevated liver enzymes.
Patients taking Stanlip-145mg should have regular monitoring of their lipid profiles and liver function. The drug should be used with caution in individuals with liver or kidney disease and should not be used in patients with gallbladder disease. There is also a potential risk of myopathy (muscle disease) when fenofibrate is used with statins, so caution is advised in such combinations.
Reviews
There are no reviews yet.